Ibrutinib Racemate (PCI-32765 Racemate) is the racemic mixture of Ibrutinib which is a highly potent and selective, covalent/irreversible, and orally bioavailable Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM, approved as an anticancer agent for treating B cell lymphoma.

纯度：≥98%

CAS：936563-87-0